ResMed Company Profile (NYSE:RMD)

ResMed trades on the New York Stock Exchange (NYSE) under the ticker symbol "RMD."

ResMed declared a quarterly dividend on Thursday, April 27th. Shareholders of record on Thursday, May 11th will be paid a dividend of $0.33 per share on Thursday, June 15th. This represents a $1.32 dividend on an annualized basis and a dividend yield of 1.71%. The ex-dividend date is Tuesday, May 9th. View ResMed's Dividend History.

ResMed Inc. (NYSE:RMD) released its quarterly earnings data on Thursday, April, 27th. The company reported $0.71 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.70 by $0.01. The company had revenue of $514.20 million for the quarter, compared to the consensus estimate of $525.84 million. ResMed had a return on equity of 22.53% and a net margin of 15.96%. The business's revenue for the quarter was up 13.3% compared to the same quarter last year. During the same quarter last year, the company earned $0.68 EPS. View ResMed's Earnings History.

10 brokerages have issued 1-year price objectives for ResMed's stock. Their predictions range from $50.00 to $72.00. On average, they anticipate ResMed's share price to reach $61.29 in the next year. View Analyst Ratings for ResMed.

Here are some recent quotes from research analysts about ResMed stock:

• 1. According to Zacks Investment Research, "In the last one month, ResMed is trading significantly above the broader Medical Products industry. On the brighter side, ResMed’s product launches and strategies to gain traction in the SDB market are expected to boost its performance in the near term. Moreover, the company’s double-digit growth in mask sales raises optimism. Its recent published favorable study result on COPD is expected to open up new scope in this line. Yet, challenges like competitive bidding and reimbursement issues continue to plague the stock. Foreign exchange movements dented third-quarter earnings, thanks to the weaker Euro and stronger Australian dollar relative to the U.S. dollar. Rising operating expenses and a weak operating margin are other major woes for ResMed. The company’s last reported fiscal third quarter performance was also unimpressive." (7/6/2017)
• 2. Needham & Company LLC analysts commented, "RMD’s revenue and EPS beat consensus in F2Q17. RMD’s gross margin was lower than expected as price declines and mix (both product and geographic) were partially offset by manufacturing efficiencies and the Brightree acquisition. However, this was offset by lower than expected SG&A and R&D expense and RMD’s operating margin beat our estimate. Despite the headline results, this wasn’t a clean quarter in our view since flow generator growth of 17% CC was helped by a few temporary factors (the AirStart liquidation and some stocking orders in China), mask growth was disappointing at 2% CC, and gross margin declined significantly on an organic basis." (1/24/2017)

Some companies that are related to ResMed include Cerner Corporation (CERN), Agilent Technologies (A), Waters Corporation (WAT), Hologic (HOLX), Varian Medical Systems (VAR), PerkinElmer (PKI), ABIOMED (ABMD), Bruker Corporation (BRKR), Alere (ALR), Accelerate Diagnostics (AXDX), Natus Medical Incorporated (BABY), Quidel Corporation (QDEL), ABAXIS (ABAX), Mazor Robotics (MZOR), Luminex Corporation (LMNX), GenMark Diagnostics (GNMK), LeMaitre Vascular (LMAT) and Accuray Incorporated (ARAY).

ResMed's management team includes the folowing people:

• Rob Douglas, President, Chief Operating Officer
• Michael Farrell, Chief Executive Officer, Director
• Brett A. Sandercock, Chief Financial Officer
• Jim Hollingshead Ph.D., President - Americas
• Anne Reiser, President – Europe & Asia Pacific
• David Pendarvis, Chief Administrative Officer, Global General Counsel, Company Secretary
• Agnes Lee, Senior Director - Investor Relations
• Peter C. Farrell Ph.D., Non-Executive Chairman of the Board
• Ron Taylor, Lead Independent Director
• Carol J. Burt, Independent Director

ResMed's stock is owned by many different of institutional and retail investors. Top institutional shareholders include APG Asset Management N.V. (0.22%), Russell Investments Group Ltd. (0.20%), Capital Investment Services of America Inc. (0.15%), Professional Advisory Services Inc. (0.13%), Rockefeller Financial Services Inc. (0.13%) and National Pension Service (0.11%). Company insiders that own ResMed stock include Anne Reiser, Brett Sandercock, Christopher G Roberts, David Pendarvis, Donald Darkin, Franz Kozich, Gary W Pace, James Hollingshead, John P Wareham, Jr Gregor K Emmert, Michael J Farrell, Peter C Farrell, Richard Sulpizio, Robert Andrew Douglas, Ronald R Taylor and Warren Russell Hawkins. View Institutional Ownership Trends for ResMed.

ResMed's stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Bank of Montreal Can, APG Asset Management N.V., Professional Advisory Services Inc., Assenagon Asset Management S.A., Financial Architects Inc, Capital Investment Services of America Inc. and US Bancorp DE. Company insiders that have sold ResMed stock in the last year include Brett Sandercock, Christopher G Roberts, David Pendarvis, Gary W Pace, James Hollingshead, John P Wareham, Michael J Farrell, Peter C Farrell, Richard Sulpizio and Ronald R Taylor. View Insider Buying and Selling for ResMed.

ResMed's stock was purchased by a variety of institutional investors in the last quarter, including Copeland Capital Management LLC, BB&T Corp, Mn Services Vermogensbeheer B.V., Gateway Investment Advisers LLC, National Pension Service, Aperio Group LLC, BTIM Corp. and West Coast Financial LLC. Company insiders that have bought ResMed stock in the last two years include Franz Kozich, Jr Gregor K Emmert, Ronald R Taylor and Warren Russell Hawkins. View Insider Buying and Selling for ResMed.

Shares of ResMed can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of ResMed stock can currently be purchased for approximately $77.19.